Collapsing Focal Segmental Glomerulosclerosis Progression to ESRD Following Combination Therapy with Pembrolizumab and Enfortumab Vedotin: A Case Report
This case report describes a 76-year-old male with pre-existing chronic kidney disease who experienced rapid, irreversible progression to end-stage renal disease due to collapsing focal segmental glomerulosclerosis following combination therapy with pembrolizumab and enfortumab vedotin, suggesting a novel synergistic mechanism of podocyte injury that warrants careful nephrology evaluation before treatment.